Regeneron


Kiniksa Wins FDA Nod For ARCALYST Injection therapy; Shares Pop After-Hours

Kiniksa Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its ARCALYST injection therapy as a first-of-its-kind treatment for adults …

Regeneron Wins FDA Nod For Evkeeza Antibody Therapy; Street Sees 34% Upside

Regeneron announced that the US Food and Drug Administration (FDA) has approved its Evkeeza antibody as a first-of-its-kind treatment for adult and pediatric …

Regeneron Scores FDA Nod For Ebola Treatment

Regeneron announced that the US Food and Drug Administration (FDA) has approved its Inmazeb anti-viral antibody as a first-of-its-kind treatment for Ebola virus infection …

Regeneron Files For Emergency Use Nod Of Covid-19 Antibody Cocktail; Shares Rise

Shares in Regeneron advanced 3.5% in Wednesday’s extended market session after the company filed for Emergency Use Authorization (EUA) with the US Food …

Regeneron Up 4% As Covid-19 Cocktail Lowers Viral Levels; Analyst Says Hold

Shares in Regeneron Pharmaceuticals are advancing 4.4% in Wednesday’s pre-market trading after the company disclosed that its investigational two-antibody cocktail, REGN-COV2, lowered viral …

Regeneron, Intellia Expand Partnership To Develop Hemophilia Treatments

Regeneron Pharmaceuticals, Inc (REGN) and Intellia Therapeutics, Inc. (NTLA) announced an expansion of their partnership to jointly develop potential products for the treatment of hemophilia …

Dane Leone Fears Regeneron Pharmaceuticals Inc Could Be Facing Big Competition from Roche

After Roche released initially reassuring datasets for its wet AMD and DME candidate, BTIG’s Dane Leone believes this spells trouble for REGN.

Roth Capital Reiterates Buy On Regeneron Pharmaceuticals Following Priority Review Acceptance For Alirocumab

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a …

J.P. Morgan Provides Key Thoughts On Regeneron Heading Into 2015

In a research report sent to investors today, J.P.

Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts